CN111278831A - 用于在涉及炎性反应的疼痛状态中镇痛的外周限制的双效κ和δ阿片样物质激动剂 - Google Patents

用于在涉及炎性反应的疼痛状态中镇痛的外周限制的双效κ和δ阿片样物质激动剂 Download PDF

Info

Publication number
CN111278831A
CN111278831A CN201880057624.3A CN201880057624A CN111278831A CN 111278831 A CN111278831 A CN 111278831A CN 201880057624 A CN201880057624 A CN 201880057624A CN 111278831 A CN111278831 A CN 111278831A
Authority
CN
China
Prior art keywords
pain
compound
acid
pharmaceutically acceptable
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880057624.3A
Other languages
English (en)
Chinese (zh)
Inventor
C.哈特里克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kevance Pharmaceutical Development Co ltd
Original Assignee
Kevance Pharmaceutical Development Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kevance Pharmaceutical Development Co ltd filed Critical Kevance Pharmaceutical Development Co ltd
Priority to CN202310638988.3A priority Critical patent/CN116440140A/zh
Publication of CN111278831A publication Critical patent/CN111278831A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dowels (AREA)
CN201880057624.3A 2017-07-06 2018-06-22 用于在涉及炎性反应的疼痛状态中镇痛的外周限制的双效κ和δ阿片样物质激动剂 Pending CN111278831A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310638988.3A CN116440140A (zh) 2017-07-06 2018-06-22 用于在涉及炎性反应的疼痛状态中镇痛的外周限制的双效κ和δ阿片样物质激动剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762529285P 2017-07-06 2017-07-06
US62/529285 2017-07-06
PCT/US2018/038936 WO2019010014A1 (en) 2017-07-06 2018-06-22 OPIOID KAPPA AND DELTA AGONIST WITH DOUBLE ACTION LIMITED TO PERIPHERY FOR ANALGESIA IN PAIN CONDITIONS INVOLVING INFLAMMATORY RESPONSE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310638988.3A Division CN116440140A (zh) 2017-07-06 2018-06-22 用于在涉及炎性反应的疼痛状态中镇痛的外周限制的双效κ和δ阿片样物质激动剂

Publications (1)

Publication Number Publication Date
CN111278831A true CN111278831A (zh) 2020-06-12

Family

ID=64950308

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310638988.3A Pending CN116440140A (zh) 2017-07-06 2018-06-22 用于在涉及炎性反应的疼痛状态中镇痛的外周限制的双效κ和δ阿片样物质激动剂
CN201880057624.3A Pending CN111278831A (zh) 2017-07-06 2018-06-22 用于在涉及炎性反应的疼痛状态中镇痛的外周限制的双效κ和δ阿片样物质激动剂

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202310638988.3A Pending CN116440140A (zh) 2017-07-06 2018-06-22 用于在涉及炎性反应的疼痛状态中镇痛的外周限制的双效κ和δ阿片样物质激动剂

Country Status (10)

Country Link
US (2) US11185551B2 (enExample)
EP (1) EP3649132B1 (enExample)
JP (1) JP7233741B2 (enExample)
KR (1) KR20200026962A (enExample)
CN (2) CN116440140A (enExample)
AU (1) AU2018297214B2 (enExample)
CA (1) CA3067398A1 (enExample)
IL (1) IL271772A (enExample)
SG (1) SG11201912036XA (enExample)
WO (1) WO2019010014A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3222543A1 (en) * 2021-06-07 2022-12-15 Uwm Research Foundation, Inc. Use of substituted 5-(4-methyl-6-phenyl-4h-benzo[f]imidazo[1,5-a][1,4] diazepin-3-yl)-1,2,4-oxadiazoles in the treatment of inflammatory conditions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800385A (en) * 1994-12-12 1998-09-01 Omeros Medical Systems, Inc. Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis
WO2002102232A2 (en) * 2001-06-14 2002-12-27 The Regents Of The University Of California A novel signaling pathway for the production of inflammatory pain and neuropathy
US20050152905A1 (en) * 2002-08-22 2005-07-14 Omoigui Osemwota S. Method of biochemical treatment of persistent pain

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015114660A1 (en) 2014-01-24 2015-08-06 Cadila Healtchare Limited Novel heterobicyclic compounds as kappa opioid agonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800385A (en) * 1994-12-12 1998-09-01 Omeros Medical Systems, Inc. Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis
WO2002102232A2 (en) * 2001-06-14 2002-12-27 The Regents Of The University Of California A novel signaling pathway for the production of inflammatory pain and neuropathy
US20050152905A1 (en) * 2002-08-22 2005-07-14 Omoigui Osemwota S. Method of biochemical treatment of persistent pain

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHAINNEL O. EANS，等: "Parallel Synthesis of Hexahydrodiimidazodiazepines Heterocyclic Peptidomimetics and Their in Vitro and in Vivo Activities at μ (MOR), δ (DOR), and κ (KOR) Opioid Receptors", 《JOURNAL OF MEDICINAL CHEMISTRY》 *

Also Published As

Publication number Publication date
US11185551B2 (en) 2021-11-30
US20210161912A1 (en) 2021-06-03
WO2019010014A1 (en) 2019-01-10
SG11201912036XA (en) 2020-01-30
CN116440140A (zh) 2023-07-18
KR20200026962A (ko) 2020-03-11
EP3649132A4 (en) 2021-04-07
CA3067398A1 (en) 2019-01-10
JP7233741B2 (ja) 2023-03-07
AU2018297214B2 (en) 2022-09-01
EP3649132B1 (en) 2023-12-27
AU2018297214A1 (en) 2020-01-16
EP3649132A1 (en) 2020-05-13
IL271772A (en) 2020-02-27
US20220288089A1 (en) 2022-09-15
JP2020525548A (ja) 2020-08-27

Similar Documents

Publication Publication Date Title
AU2010306114B2 (en) Compositions comprising tramadol and celecoxib in the treatment of pain
Varkonyi et al. Current options and perspectives in the treatment of diabetic neuropathy
US20040209850A1 (en) Methods of treating pain and compositions for use therefor
CN111902140A (zh) 用于预防或治疗瘙痒的含有作为活性成分的hdac6抑制剂的药物组合物
JP2017506244A (ja) ノルイボガイン及び関連化合物を用いた治療方法
JP2021138703A (ja) オピオイドとｎ−アシルエタノールアミンの組み合わせ
Camilleri Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome.
Ghorbanzadeh et al. Involvement of opioid receptors in the systemic and peripheral antinociceptive actions of montelukast in the animal models of pain
HK1248124A1 (zh) 用於治疗肥胖症和肥胖症相关疾病的包含卡格列净和芬特明的协同治疗
González-Rodríguez et al. Involvement of enkephalins in the inhibition of osteosarcoma-induced thermal hyperalgesia evoked by the blockade of peripheral P2X3 receptors
US20220288089A1 (en) Peripherally-restricted dual-acting kappa and delta opioid agonist for analgesia in pain states involving the inflammatory response
US20150110865A1 (en) Cns stimulant and opioid receptor antagonist combination as a non-addictive, non-aversive and synergistic anti-obesity treatment
WO2016005897A1 (en) Combination of pregabalin and meloxicam for the treatment of neuropathic pain
WO2024091863A1 (en) Combinatorial, and rotational combinatorial therapies for obesity and other diseases
Dobrek et al. Current management and future perspectives of overactive bladder (OAB) pharmacotherapy
WO2017180064A1 (en) A drug for the effective control of acute and/or chronic pain and a method for its administration
KR101841238B1 (ko) Trpc3의 억제제를 유효성분으로 포함하는 가려움증 치료용 약제학적 조성물
JP5856613B2 (ja) 過敏性腸症候群の治療において使用するためのタペンタドール
Akiyode et al. Diabetic neuropathy: what
CN120478320A (zh) N-棕榈酰乙醇酰胺用于与非甾体抗炎药组合治疗炎性疼痛
HK40062167A (en) A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl
Tillisch et al. T1261 The Effect of Chronic Neurokinin-1 Receptor Antagonism On Sympathetic Nervous System Activity in Irritable Bowel Syndrome (IBS)
HK40032679A (en) Fixed dose composition of paracetamol: amitriptyline and method for the treatment of mixed cancer pain
Kitazawa et al. T1260 Ghrelin Stimulates Gastric Motility Through Activation of the Vago-Vagal Reflex Pathway in the Anesthetized Guinea-Pig
Moennikes et al. T1263 Pantoprazole Treatment Reduces Non-GERD Symptoms in Patients Suffering from Erosive GERD, Functional Dyspepsia (FD), and/or Irritable Bowel Syndrome (IBS)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20200612

RJ01 Rejection of invention patent application after publication